Overview

Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BAY73-4506 treatment is safe and can shrink or delay the growth of tumors in patients with unresectable liver cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer